EUVIMEDEUVIMED entdecken
Crossref

Loxenatide Alleviates High Glucose-Induced Pancreatic β-Cell Senescence via Regulating the PERK/eIF2α Pathway

Junfang Yuan, Yuzhong Wang, Defeng Wang, Han Yan, Ning Wang

Hormone and Metabolic Research · 01.12.2024 · 56 (12) · 890-899

DOI: 10.1055/a-2407-9360 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hormone and Metabolic Research, erschienen am 01.12.2024. Verfasst von Junfang Yuan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Affiliated Hospital of Hebei University of Engineering, Handan City, Hebei Province, China. Hauptthemen laut MEDLINE: Insulin-Secreting Cells, Cellular Senescence, eIF-2 Kinase, Eukaryotic Initiation Factor-2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Health Commission of Hebei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide-1 (GLP-1) receptor agonists are effective hypoglycemic agents for type 2 diabetes mellitus (T2DM). It was reported that T2DM was implicated in pancreatic β-cell senescence. Whether loxenatide regulates cellular senescence of pancreatic β-cells is to be investigated. Our results revealed that high glucose (HG)-induced cellular senescence and elevated expression of SASP factors inhibited cell proliferation and stimulated DNA damage, which were reversed by loxenatide treatment. In addition, HG induction resulted in promoted insulin secretion and insulin synthesis of pancreatic β-cells and loxenatide treatment further strengthened these influences. In addition, loxenatide could inactivate the PERK/eIF2α signaling pathway via decreasing the levels of p-PERK and p-eIF2α in HG-induced pancreatic β-cells. Furthermore, CCT020312, an activator of the PERK/eIF2α signaling pathway, abolished loxenatide-mediated inhibiting cellular senescence, elevating cell proliferation and improving DNA damage and enhancing insulin secretion of HG-induced pancreatic β-cells. In conclusion, our results indicated that loxenatide impeded cellular senescence, promoted cell proliferation, improved DNA damage, enhanced insulin secretion and insulin synthesis of HG-induced pancreatic β-cells through modulating the PERK/eIF2α signaling pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin-Secreting CellsCellular SenescenceeIF-2 KinaseEukaryotic Initiation Factor-2GlucoseSignal TransductionCell ProliferationDNA DamageAnimalsHumansInsulinMiceCell Line

Substanzen

eIF-2 KinaseEukaryotic Initiation Factor-2GlucoseInsulinEIF2AK3 protein, human

Autor:innen und Institutionen

  • Department of Endocrinology, Affiliated Hospital of Hebei University of Engineering, Handan City, Hebei Province, China.
  • Department of Urology, Affiliated Hospital of Hebei University of Engineering, Handan City, Hebei Province, China.

Förderung

  • Health Commission of Hebei Province

Zitieren

APA

Yuan, J., Wang, Y., Wang, D., Yan, H., & Wang, N. (2024). Loxenatide Alleviates High Glucose-Induced Pancreatic β-Cell Senescence via Regulating the PERK/eIF2α Pathway. Hormone and Metabolic Research, 56(12), 890-899. https://doi.org/10.1055/a-2407-9360

Vancouver

Yuan J, Wang Y, Wang D, Yan H, Wang N. Loxenatide Alleviates High Glucose-Induced Pancreatic β-Cell Senescence via Regulating the PERK/eIF2α Pathway. Hormone and Metabolic Research. 2024;56(12):890-899. doi:10.1055/a-2407-9360

BibTeX
@article{Yuan2024,
  author = {Yuan, Junfang and Wang, Yuzhong and Wang, Defeng and Yan, Han and Wang, Ning},
  title = {Loxenatide Alleviates High Glucose-Induced Pancreatic β-Cell Senescence via Regulating the PERK/eIF2α Pathway},
  journal = {Hormone and Metabolic Research},
  year = {2024},
  volume = {56},
  number = {12},
  pages = {890--899},
  doi = {10.1055/a-2407-9360}
}
Kostenlos starten →